Sentences with phrase «by these drugs over»

With the loss of magnesium, all of the symptoms being «treated» by these drugs over time inevitably become worse.

Not exact matches

Studies commissioned by his group project that over the next decade, PBMs will save employers, consumers, and the government more than $ 2 trillion, and have already helped reduce by a third the projected cost of the Medicare Part D program, a largely privatized drug benefit for seniors.

Walmsley, who took over a year ago, is focusing on rebuilding GSK's drug pipeline by overhauling research and appointing heavyweight outsiders, such as veteran Roche scientist Hal Barron.

And for 27 years, before he was elected sheriff, he presided over court cases — ones that increasingly involved the stories of lives undone by drugs and poverty, and of an opioid epidemic taking root.

Despite this threat, and looming competition from a new Gilead Sciences HIV drug, GSK sees growth strengthening over the next few years, helped by the roll - out of newer medicines.

Second, approval rates by the U.S. Food and Drug Administration have steadily risen over the past two decades, climbing from 23 percent in 1994 to 89 percent and 77 percent in 2014 and 2015, respectively.

The company is selling a thing (the kit) by saying it can provide «health reports on 254 diseases and conditions,» including categories such as «carrier status,» «health risks,» and «drug response,» and specifically as a «first step in prevention» that enables users to «take steps toward mitigating serious diseases» such as diabetes, coronary heart disease, and breast cancer...» Most of the uses «listed on your website, a list that has grown over time,» the FDA writes, «are medical device uses [for the] Personal Genome Service.»

The memory - eating disease, expected to afflict 15 million Americans by 2060 (and tens of millions more around the world as life expectancy increases), has no cure; a new drug for the condition hasn't been approved in well over a decade; initially promising experimental treatments seem to be failing with clockwork regularity; and there's not even a definitive consensus on what, exactly, biopharma companies should focus on while developing Alzheimer's medicines.

Product safety is unusually sensitive in China following scandals over the past decade in which infants, hospital patients and others have been killed or sickened by phoney or adulterated milk powder, drugs and other goods.

Although the FDA can't dictate prices or reject therapies over pricing concerns (they can only focus on safety and efficacy), the agency can encourage more competition through moves like this (as well as speedier approval pathways) which could spur drug makers to produce products that ultimately lower costs for patients — a goal cited by FDA Commissioner Scott Gottlieb in announcing the list.

The 32 - year - old CEO of Turing Pharmaceuticals became a target of widespread ire in September when he boosted the price of the toxoplasmosis treatment Daraprim by over 5,000 % after acquiring the drug in August.

«The manufacturer of a drug has no influence or control over the prices charged by a secondary wholesaler to a hospital or pharmacy,» reads part of a statement on the PhRMA web site, the industry's trade association group.

Cost - cutting by health insurers and concerns over drug pricing have made CVS's pharma - benefits unit seem like a liability to some investors; and in the head - to - head fight, Walgreens has grabbed some market share.

The group emerged in Colombia over the last decade, moving into areas of the drug trade vacated by Colombian cartels and paramilitary groups and becoming a kind of decentralized network of nodes running criminal activities throughout the country.

The combined company could initially have annual sales of over $ 65 billion, but there has been speculation that the merger could quickly be followed by a spinoff of some lower - margin businesses, including drugs that have lost patent protection.

Pfizer also came under fire over drug price increases including a record $ 107 million fine by U.K. regulators for hiking an epilepsy treatment's price by 2,600 %.

Drug companies including Purdue Pharma LP and Johnson & Johnson have been fighting lawsuits by two California counties, the city of Chicago, four counties in New York and the state of Mississippi over their opioid marketing practices.

While the drug maker has responded to the massive backlash over its extravagant price increase on the device by boosting its patient assistance programs and introducing an authorized generic EpiPen version at half the cost, CVS» topline price will still be significantly cheaper.

In order for the drug to be cost effective, drugmakers should slash the price of the drug by over two thirds — to $ 4,536, when patients would be spending about $ 100,000 to keep themselves healthy, the researchers wrote in the JAMA article.

Sprout's controversial pink libido pill was approved on Tuesday by the U.S. Food and Drug Administration for pre-menopausal women, after being rejected twice over concerns about its effectiveness and side - effects.

These risks and uncertainties include: Gilead's ability to achieve its anticipated full year 2018 financial results; Gilead's ability to sustain growth in revenues for its antiviral and other programs; the risk that private and public payers may be reluctant to provide, or continue to provide, coverage or reimbursement for new products, including Vosevi, Yescarta, Epclusa, Harvoni, Genvoya, Odefsey, Descovy, Biktarvy and Vemlidy ®; austerity measures in European countries that may increase the amount of discount required on Gilead's products; an increase in discounts, chargebacks and rebates due to ongoing contracts and future negotiations with commercial and government payers; a larger than anticipated shift in payer mix to more highly discounted payer segments and geographic regions and decreases in treatment duration; availability of funding for state AIDS Drug Assistance Programs (ADAPs); continued fluctuations in ADAP purchases driven by federal and state grant cycles which may not mirror patient demand and may cause fluctuations in Gilead's earnings; market share and price erosion caused by the introduction of generic versions of Viread and Truvada, an uncertain global macroeconomic environment; and potential amendments to the Affordable Care Act or other government action that could have the effect of lowering prices or reducing the number of insured patients; the possibility of unfavorable results from clinical trials involving investigational compounds; Gilead's ability to initiate clinical trials in its currently anticipated timeframes; the levels of inventory held by wholesalers and retailers which may cause fluctuations in Gilead's earnings; Kite's ability to develop and commercialize cell therapies utilizing the zinc finger nuclease technology platform and realize the benefits of the Sangamo partnership; Gilead's ability to submit new drug applications for new product candidates in the timelines currently anticipated; Gilead's ability to receive regulatory approvals in a timely manner or at all, for new and current products, including Biktarvy; Gilead's ability to successfully commercialize its products, including Biktarvy; the risk that physicians and patients may not see advantages of these products over other therapies and may therefore be reluctant to prescribe the products; Gilead's ability to successfully develop its hematology / oncology and inflammation / respiratory programs; safety and efficacy data from clinical studies may not warrant further development of Gilead's product candidates, including GS - 9620 and Yescarta in combination with Pfizer's utomilumab; Gilead's ability to pay dividends or complete its share repurchase program due to changes in its stock price, corporate or other market conditions; fluctuations in the foreign exchange rate of the U.S. dollar that may cause an unfavorable foreign currency exchange impact on Gilead's future revenues and pre-tax earnings; and other risks identified from time to time in Gilead's reports filed with the U.S. Securities and Exchange Commission (the SDrug Assistance Programs (ADAPs); continued fluctuations in ADAP purchases driven by federal and state grant cycles which may not mirror patient demand and may cause fluctuations in Gilead's earnings; market share and price erosion caused by the introduction of generic versions of Viread and Truvada, an uncertain global macroeconomic environment; and potential amendments to the Affordable Care Act or other government action that could have the effect of lowering prices or reducing the number of insured patients; the possibility of unfavorable results from clinical trials involving investigational compounds; Gilead's ability to initiate clinical trials in its currently anticipated timeframes; the levels of inventory held by wholesalers and retailers which may cause fluctuations in Gilead's earnings; Kite's ability to develop and commercialize cell therapies utilizing the zinc finger nuclease technology platform and realize the benefits of the Sangamo partnership; Gilead's ability to submit new drug applications for new product candidates in the timelines currently anticipated; Gilead's ability to receive regulatory approvals in a timely manner or at all, for new and current products, including Biktarvy; Gilead's ability to successfully commercialize its products, including Biktarvy; the risk that physicians and patients may not see advantages of these products over other therapies and may therefore be reluctant to prescribe the products; Gilead's ability to successfully develop its hematology / oncology and inflammation / respiratory programs; safety and efficacy data from clinical studies may not warrant further development of Gilead's product candidates, including GS - 9620 and Yescarta in combination with Pfizer's utomilumab; Gilead's ability to pay dividends or complete its share repurchase program due to changes in its stock price, corporate or other market conditions; fluctuations in the foreign exchange rate of the U.S. dollar that may cause an unfavorable foreign currency exchange impact on Gilead's future revenues and pre-tax earnings; and other risks identified from time to time in Gilead's reports filed with the U.S. Securities and Exchange Commission (the Sdrug applications for new product candidates in the timelines currently anticipated; Gilead's ability to receive regulatory approvals in a timely manner or at all, for new and current products, including Biktarvy; Gilead's ability to successfully commercialize its products, including Biktarvy; the risk that physicians and patients may not see advantages of these products over other therapies and may therefore be reluctant to prescribe the products; Gilead's ability to successfully develop its hematology / oncology and inflammation / respiratory programs; safety and efficacy data from clinical studies may not warrant further development of Gilead's product candidates, including GS - 9620 and Yescarta in combination with Pfizer's utomilumab; Gilead's ability to pay dividends or complete its share repurchase program due to changes in its stock price, corporate or other market conditions; fluctuations in the foreign exchange rate of the U.S. dollar that may cause an unfavorable foreign currency exchange impact on Gilead's future revenues and pre-tax earnings; and other risks identified from time to time in Gilead's reports filed with the U.S. Securities and Exchange Commission (the SEC).

With recent uproar over drug price hikes by Valeant (vrx), Mylan (myl) and Martin Shkreli, healthcare experts have reached a consensus: The system as we know it is officially broken.

The political cloud over Attorney General Jeff Sessions» decision to step back from any investigation touching the Trump campaign may have a silver lining for a law enforcement officer who appears preoccupied by violent crime, drugs and immigration.

Further, I showed that Pharma's IRR has followed a rapid and steady linear decline over 20 years, which is consistent with recent estimates from BCG and Deloitte, and can be fully explained by the Law of Diminishing Returns as a natural and unavoidable consequence of prioritizing a limited set of investment opportunities while each new drug raises the bar for the next.

Shoppers Drug Mart shareholders, who will own approximately 29 % of the combined company, stand to benefit from substantial upside over the long - term, driven by the combined company's strategic position and achievement of full run - rate synergies.

The comments, made at a conference organized by a leading U.S. health insurer lobbying group, stoked speculation over what steps the administration of U.S. President Donald Trump may take to rein in lofty prescription drug costs.

U.S. Food and Drug Administration chief Scott Gottlieb on Thursday questioned whether rebates that drugmakers provide to health insurers should remain protected by federal law, sparking new concerns on Wall Street over efforts to curb drug pricDrug Administration chief Scott Gottlieb on Thursday questioned whether rebates that drugmakers provide to health insurers should remain protected by federal law, sparking new concerns on Wall Street over efforts to curb drug pricdrug pricing.

But the company was hit by regulatory and political scrutiny in the past year over its drug pricing and its relationship to a mail - order pharmacy, and its stock took a beating.

By acquiring Humana, Walmart gains preferential access to seniors through Humana Medicare advantage, and leverage over pharmaceutical manufacturers to negotiate for lower drug prices.

Specialty pharmaceuticals have contributed substantially to the rise in the nation's drug costs over the last several years, and these costs are projected to increase by more than 65 % by the end of 2017.

Bayer said in a statement that it doesn't control the cost for patients at the pharmacy, because copays are determined by insurers and pharmacy - benefit managers — an argument that pharmaceuticals companies have long made when facing criticism over drug prices.

Stada's owners are also mulling bids for the generic drug business being sold by Sanofi, the sources said, and might favor this combination over Merck as generic drugs are typically valued at a cheaper multiple.

Antares Pharma (ATRS)- The company possesses a strong pipeline of drug / device combination product candidates which provide better treatment options in a variety of disease settings - Xyosted could potentially be approved by September and should see significant adoption due to several advantages over current treatments (keep in mind global male hypogonadism market to exceed $ 3 billion within 10 years).

Conservative foundations, multinational oil companies and a prescription drug maker were the most frequent sponsors of more than 100 expense - paid educational seminars attended by federal judges over a 4 1/2 - year period, according to a Center for Public Integrity investigation.

Educational Session # 1: When: June 3rd, Wednesday, 3:15 PM — 4:00 PM Where: Institute 2015 Pre-conference Cybersecurity, Technology and Infrastructure Advancements Forum What: Optimize PBM Value Proposition to Payers through Disruptive Innovation by Terry Ramey, EVP, Business Development and Client Engagement Session Details: PBMs that manage over $ 300 billion of pharmacy benefits for plan sponsors have historically been challenged to support plan sponsors» goals to reduce avoidable drug - impacted medical costs and optimize overall pharmacy costs.

Lets talk about psychotropic drugs and our over drugged children by the «psych / pharma» complex that has become tyrannical in it's quest for money, stop demonizing guns.

The report found that a black driver who was pulled over was twice as likely to be searched by police as a white driver, even though searches of white drivers were more likely to turn up drugs or illegal weapons.

Imagine a drug that helped you lose a stone in weight over the course of a year, reduced your chances of being overweight by 42 % and increased your daily...

Airwaves are filled with commercials for antidepressants; by sales, the antipsychotic medication aripiprazole, marketed for depression, is the number - one drug in the U.S., with sales of well over a billion dollars per year.

The late 1970s were filled with «excessive and over-the-top drug use,» as described by one Scorsese biographer, and he would have four different marriages end over the span of 1970 to 1995.

In their filing attorney's wrote the mandate, «runs roughshod over Wheaton's religious beliefs, and the beliefs of millions of other Americans, by forcing it to provide health insurance coverage for abortifacient drugs and related education and counseling.»

Officials and journalists are being gunned down on the streets, civilian homes are being raided and seized, civilian government is increasingly being taken over by the military — and so far the drug lords have only engaged in selective terrorism.

The Lord revealed that the problem was with my heart it is so wicked and deceptive i still believed that i was a good person i did nt drink or take drugs smoke or swear i wasnt violent i had some hangups but kept them to myself but this wicked thought was the reason why i couldnt get free.That was enough for the enemy to bring guilt and condemnation upon me.So when i confessed that my heart was indeed wicked and that i needed a new heart.I was instantly delivered and set free from the past and have not looked back though i am sometimes reminded by others for what i did wrong.It no longer has power over me.I believe we all struggle with two areas as christians we must confess our sin and we must confess our pride for without him we can do nothing.May the Lord show you what it is that is blocking you from receiving his love and forgiveness the issue will be found in your heart ask the Lord to reveal it for what it is.We do nt like to see the truth its ugly and i am sorry if this offends you it wasnt my intention.May he set you free as he has done for me.regards brentnz

Consider the case of Tom Lawlor whose career in MMA is effectively over having had a positive drug test and having been unable to find a tainted supplement to offer by way of explanation for it.

But questions remain: Should athletes be permitted to gain an advantage over their competitors by artificial means, and, further, should they be permitted to take drugs that have demonstrably harmful side effects?

Jan 04,2016... Major League Baseball, once chided by Congress and fought by the players» association over its drug -...

* Curiosities about same sex stimulation, I think many men have these curiosities and it messes with them mentally, either they act on it or divulge in gay porn I DO NT THINK THATS TRUE UNLESS THEY ARE IN PRISON * Addiction to porn and / or jacking off ONLY WHEN GETTING IT FROM THEIR WIFE IS SUCH A CHORE * Medical Conditions such as low sex drive, he is older and it has been going down over the years, he has high blood pressure and takes medication, he also has low Vitamin D and takes supplements, he may have some ED issues as well LACK OF SEX COULD CAUSE AS WELL AS BE CAUSED BY THOSE FACTORS * Sexual advances from other woman and him acting on those or seeking out other women for comfort when he is angry and / or depressed A DEFINITE POSSIBILITY * His ADHD doesn't allow him to process issues normally, he is quick to anger, depression, and feeling disrespected that causes his to retreat * He was self raised, came from drug infested household where neglect, torture, and narcissism ruled, and he lost his mother at the age of 7 from drugs, growing up in foster care * I make more money and I control all the money, he is not interested in paying bills at all, this immaculateness him * He is a control freak and sex is his way of controlling me, where he otherwise can't control me as I am more educated and he is more vocational SOUNDS TO ME LIKE YOU ARE A MATCHED PAIR IN THAT RESPECT.

Who allows themself to be repeatedly drugged by the same person over and over when you have your own apartment to return to?

While there is no concrete proof that BPA is harmful to humans, some tests by the National Toxicology Program (NTP), the National Institutes of Health, as well as the Food & Drug Administration (FDA) have shown that there could be potential issues that could arise due to over exposure of this chemical.

* Editor's Note: This article is an excerpt from Life Over the Influence, a new program created by Kimberly Abraham LMSW and Marney Studaker - Cordner LMSW, therapists and experts in helping families whose members are struggling with alcohol or drug use.